Risk factors for venous thromboembolism (VTE) are often modifiable and overlap with risk
factors for coronary artery disease. Encouraging our patients to adopt a heart-healthy …

The 4th World Symposium on Pulmonary Hypertension was the first international meeting to
focus not only on pulmonary arterial hypertension (PAH) but also on the so-called non-PAH …

The task of developing ESC Guidelines covers not only the integration of the most recent
research, but also the creation of educational tools and implementation programmes for the …

Background Riociguat, a member of a new class of compounds (soluble guanylate cyclase
stimulators), has been shown in previous clinical studies to be beneficial in the treatment of …

Methods A writing group was established with representation from the Council on Peripheral
Vascular Disease and Council on Cardiopulmonary, Critical Care, Perioperative and …

Background—Chronic thromboembolic pulmonary hypertension (CTEPH) is often a sequel
of venous thromboembolism with fatal natural history; however, many cases can be cured by …

OBJECTIVE: Pulmonary endarterectomy is a curative surgical treatment option for the
majority of patients with chronic thromboembolic pulmonary hypertension. The current …

Background Treprostinil, a prostacyclin analogue, is effective for the treatment of pulmonary
arterial hypertension. However, information is scarce regarding treprostinil for treatment of …

Traditional concepts of the pathogenesis of chronic thromboembolic pulmonary
hypertension (CTEPH) invoke a thromboembolic origin. However, neither classic plasmatic …

Objective To examine the effect of balloon pulmonary angioplasty (BPA) on chronic
thromboembolic pulmonary hypertension (CTEPH) in patients with inoperable disease or …